Erythromelalgia Treatment Market

Erythromelalgia is a rare condition that primarily affects the feet and it is characterized by intense, burning pain of affected extremities, severe redness (erythema), and increased skin temperature that may be episodic or almost continuous in nature.The specific cause of erythromelalgia remains unknown. Erythromelalgia is a result of vasomotor abnormalities or dysfunction in the normal narrowing and widening of the diameter of certain blood vessels, leading to abnormalities of blood flow to the extremities.Females are more affected than males. Disorder onset occurs most commonly in middle age; however, associated symptoms may develop at any age.

Erythromelalgia Treatment Market contains market size and forecasts of Erythromelalgia Treatment in Global, including the following market information:

• Global Erythromelalgia Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Erythromelalgia Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

by Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Erythromelalgia Treatment include Teva Pharmaceutical Industries Ltd, Biogen, Pfizer Inc, Akorn, Novartis AG, Galderma SA, Acorda Therapeutics, Inc, AbbVie and Amneal Pharmaceuticals LLC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Erythromelalgia Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Erythromelalgia Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Erythromelalgia Treatment Market Segment Percentages, by Type, 2021 (%)

by Treatment

• Drugs
• Therapy

by Route of Administration

• Oral
• Inhalation
• Others

Global Erythromelalgia Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Erythromelalgia Treatment Market Segment Percentages, by Application, 2021 (%)

• Primary Erythromelalgia
• Secondary Erythromelalgia

Global Erythromelalgia Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Erythromelalgia Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Erythromelalgia Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Erythromelalgia Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Teva Pharmaceutical Industries Ltd
• Biogen
• Pfizer Inc
• Akorn
• Novartis AG
• Galderma SA
• Acorda Therapeutics, Inc
• AbbVie
• Amneal Pharmaceuticals LLC
• Xenon Pharmaceuticals Inc
• Ligand Pharmaceuticals Incorporated
• Zydus Cadila
• ANI Pharmaceuticals, Inc
• Lupin Limited
• Bausch Health
• Indoco Remedies Ltd